申请人:Hoffmann-La Roche Inc.
公开号:US05278148A1
公开(公告)日:1994-01-11
Compounds of the formula ##STR1## wherein R.sup.1 is hydrogen or methyl, R.sup.2 is ethyl, propyl, isopropyl, imidazol-2-yl, imidazol-4-yl, pyrazol-3-yl, thiazol-4-yl, thien-2-yl, ethoxycarbonyl, t-butylcarbonylmethyl, benzyloxycarbonylmethyl or t-butoxy, R.sup.3 is isobutyl, cyclohexylmethyl or benzyl, R.sup.4 is nitro, amino or a group of the formula --N(R.sup.5)(R.sup.6) and A is one of the groups ##STR2## wherein R.sup.5 and R.sup.6 is alkyl or alkoxyalkyl; or optionally substituted phenyl, phenylalkyl or phenylsulfonylalkyl among others with the proviso that A is not group (b) when R.sup.6 is alkanoyl, alkoxycarbonyl or arylalkoxycarbonyl, the dotted line can be an additional bond, R.sup.7 is phenyl or substituted phenyl and R.sup.8 is hydrogen or organocarbonylalkyl, with the proviso that R.sup.8 is not alkoxycarbonylamino or arylalkoxycarbonylamino when R.sup.7 is phenyl, benzyl or .alpha.-naphthyl, Y is a bivalent residue in the form of optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates or mixtures of diastereomeric racemates as well as pharmaceutically usable salts thereof inhibit the activity of the natural enzyme renin and can accordingly be used in the control or prevention of high blood pressure and cardiac insufficiency.
该化合物的公式为##
STR1##其中R.sup.1为
氢或
甲基,R.sup.2为乙基、丙基、
异丙基、
咪唑-2-基、
咪唑-4-基、
吡唑-3-基、
噻唑-4-基、
噻吩-2-基、乙
氧羰基、叔丁基羰基
甲基、苄
氧羰基
甲基或叔丁
氧基,R.sup.3为异丁基、
环己基
甲基或
苄基,R.sup.4为硝基、
氨基或式--N(R.sup.5)(R.sup.6)的基团,A为以下之一的基团##
STR2##其中R.sup.5和R.sup.6为烷基或烷
氧基烷基;或可选的取代
苯基、
苯基烷基或
苯基磺酰基烷基等,但须注意当R.sup.6为烷酰基、烷
氧羰基或芳基烷
氧羰基时,A不是(b)基团;虚线可以是额外的键,R.sup.7为
苯基或取代的
苯基,R.sup.8为
氢或有机羰基烷基,但须注意当R.sup.7为
苯基、
苄基或α-
萘基时,R.sup.8不是烷
氧羰基
氨基或芳基烷
氧羰基
氨基,Y为光学纯对映体残基、对映体混合物、对映体外消旋体或对映体外消旋体混合物,以及其药学上可用的盐,能抑制
天然酶肾素的活性,因此可用于控制或预防高血压和心脏功能不全。